Novel Cell Culture Derived Influenza Vaccines
The disadvantages of the conventional production methodology, including possible shortage of eggs in a pandemic situation, selection of egg-adapted variants have repeatedly emphasized the necessity for production of influenza vaccines on a well characterized and stable cell line.
The continuous monkey kidney cell line, known as Vero, has previously been accepted by regulatory authorities in Europe and the US for human vaccine products such as poliomyelitis and rabies vaccines. The excellent safety record of Vero cells used in the production of biologicals has been demonstrated by the consumption of more than one hundred million doses of the Vero cell derived polio vaccine over the last 18 years worldwide in nearly 60 countries.
Baxter’s influenza vaccine, currently in the late stage development, will be the first in the industry to be based on Vero cell continuous cell line. It is completely free from egg proteins, which minimizes the risk of allergic reactions, exposure to antibiotics, and free of the preservative thiomersal.
Today, this economic technology of influenza vaccine production represents the most modern and reliable way to maintain high quality standards of the product and to ensure sufficient quantities of vaccines in emergency situations.